Eletriptan Hydrobromide 143322-58-1

inquire about Eletriptan Hydrobromide
Eletriptan Hydrobromide

Eletriptan (also known as eletriptan hydrobromide) is a second generation triptan drug marketed and manufactured by Pfizer Inc for the treatment of migraine headaches. It is sold in the US under the brand name Relpax

.

Approval and availability

Eletriptan was approved by the U. S. Food and Drug Administration (FDA) on December 26, 2002 for the acute treatment of migraine with or without aura in adults. It is available only by prescription in the United States and Canada. It is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine. It is available in 20 mg and 40 mg strengths. Eletriptan is covered by {{US patent5545644U. S. Patent no. 5545644

read more [+]
Systematic (IUPAC) name: (R)-3-[(-1-methylpyrrolidin-2-yl)methyl]-5-(2-phenylsulfonylethyl)- 1H-indole
Eletriptan Hydrobromide CAS number: 143322-58-1
ATC code: N02CC06
PubChem: 77993
DrugBank: APRD00945
Formula: C22H26N2O2
Molecular mass: 382.52 g/mol
Eletriptan Hydrobromide Assay/Purity: Typically NLT 98%
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.